iShares Microcap ETF (IWC)

The company said that the Air-Launched Rapid Response Missile is expected to deliver nearly hypersonic speed and long range at a fraction of the cost of other hypersonic weapons.

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.

The company said upon closing of the final transaction with an institutional investor its outstanding debt will be reduced by approximately $37.9 million.

The company said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period.

AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.

Recent expansion updates, a surge in retail interest, and a low stock float appear to be powering the stock.

Owlet said that for the first quarter of 2026, it expects revenue in the range of $20 to $21 million. The forecast was significantly lower than Wall Street expectations of $26.2 million.

Palladyne AI reported a loss of $0.04 per share, down from a loss of $1.75 per share during the same quarter a year ago, and better than Wall Street’s expectations of a loss of $0.14 per share.

The company announced an agreement to be acquired by Royal Cup Coffee & Tea in an all-cash deal valued at $1.29 per share.

The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.

Brokerages cut the stock’s price target after the company reported a 38% decline in fourth-quarter revenue.

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

KORE stated that Searchlight and Abry will acquire all shares of the company’s issued and outstanding common stock that they currently don’t own in an all-cash transaction valued at nearly $726 million.

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

Cipher’s fourth-quarter revenue came in at $60 million, significantly below the consensus estimates of $85.7 million, according to Fiscal.ai data.

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

The company said that it has filed a third-party, independent Technical Report updating its Mineral Resource estimate with an effective date of January 21, 2026.

The company said it expects $115 million to $120 million in revenue for fiscal year 2027, however analysts on average were expecting the revenue of $85.23 million, as per data from fiscal.ai.

The company announced the acquisition of ad-tech firm IndiCue for up to $40 million in total consideration.

The company announced pricing for a $12 million public offering at an 8% discount to Thursday’s close.

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.